I totally agree with you. Statistically the numbers may have been better if the FDA had no concerns about the efficacy of the drug and did not ask VERU to stop the trials. I am afraid the FDA screwed us and wonder who paid them off to give us the denial. Every drug I see on TV indicates the side effects can be death, suicide thoughts, kidney failure, liver disease, COPD , etc. etc. We have a safe drug and it gets shoved up our rear ends.
Recent VERU News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/13/2026 01:19:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 01:09:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 11:00:07 AM
- Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress • GlobeNewswire Inc. • 05/13/2026 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 09:10:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 08:59:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 08:45:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 08:34:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 08:20:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 08:10:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 07:59:51 PM
- Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th • GlobeNewswire Inc. • 05/06/2026 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/16/2026 04:15:18 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/07/2026 08:18:22 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 04/07/2026 08:11:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 08:04:22 PM
- Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss • GlobeNewswire Inc. • 03/09/2026 12:30:00 PM
- Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/19/2026 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 03:32:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 12:00:14 PM
- Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress • GlobeNewswire Inc. • 02/11/2026 11:30:00 AM
- Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th • GlobeNewswire Inc. • 02/04/2026 01:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/28/2026 09:07:48 PM
